|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Song YW, Lim Y and Cho SK:
2,4-Di-tert-butylphenol, a potential HDAC6 inhibitor, induces
senescence and mitotic catastrophe in human gastric adenocarcinoma
AGS cells. Biochim Biophys Acta Mol Cell Res. 1865:675–683. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goscinski MA, Larsen SG, Warloe T, Stoldt
S, Nesland JM, Suo ZH and Giercksky KE: Adenocarcinomas on the
rise-does it influence survival from oesophageal cancer? Scand J
Surg. 98:214–220. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ruf C, Thomusch O, Goos M, Makowiec F,
Illerhaus G and Ruf G: Impact of neoadjuvant chemotherapy with
PELF-protocoll versus surgery alone in the treatment of advanced
gastric carcinoma. BMC Surg. 14:52014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Finn RS, Dering J, Conklin D, Kalous O,
Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al: PD
0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially
inhibits proliferation of luminal estrogen receptor-positive human
breast cancer cell lines in vitro. Breast Cancer Res. 11:R772009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Beaver JA, Amiri-Kordestani L, Charlab R,
Chen W, Palmby T, Tilley A, Zirkelbach JF, Yu J, Liu Q, Zhao L, et
al: FDA approval: Palbociclib for the treatment of postmenopausal
patients with estrogen receptor-positive, HER2-negative metastatic
breast cancer. Clin Cancer Res. 21:4760–4766. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bollard J, Miguela V, Ruiz de Galarreta M,
Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sánchez P,
Nguyen CB, et al: Palbociclib (PD-0332991), a selective CDK4/6
inhibitor, restricts tumour growth in preclinical models of
hepatocellular carcinoma. Gut. 66:1286–1296. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Michel L, Ley J, Wildes TM, Schaffer A,
Robinson A, Chun SE, Lee W, Lewis J Jr, Trinkaus K and Adkins D:
Phase I trial of palbociclib, a selective cyclin dependent kinase
4/6 inhibitor, in combination with cetuximab in patients with
recurrent/metastatic head and neck squamous cell carcinoma. Oral
Oncol. 58:41–48. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang J, Zhou L, Zhao S, Dicker DT and
El-Deiry WS: The CDK4/6 inhibitor palbociclib synergizes with
irinotecan to promote colorectal cancer cell death under hypoxia.
Cell Cycle. 16:1193–1200. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Valenzuela CA, Vargas L, Martinez V, Bravo
S and Brown NE: Palbociclib-induced autophagy and senescence in
gastric cancer cells. Ex Cell Res. 360:390–396. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bolós V, Grego-Bessa J and de la Pompa JL:
Notch signaling in development and cancer. Endocr Rev. 28:339–363.
2007. View Article : Google Scholar
|
|
12
|
Giovannini C, Gramantieri L, Minguzzi M,
Fornari F, Chieco P, Grazi GL and Bolondi L: CDKN1C/P57 is
regulated by the notch target gene hes1 and induces senescence in
human hepatocellular carcinoma. Am J Pathol. 181:413–422. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu J, Yu J, Gan J, Song N, Shi L, Liu J,
Zhang Z and Du J: Notch1/2/3/4 are prognostic biomarker and
correlated with immune infiltrates in gastric cancer. Aging (Albany
NY). 12:2595–2609. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Revandkar A, Perciato ML, Toso A, Alajati
A, Chen J, Gerber H, Dimitrov M, Rinaldi A, Delaleu N, Pasquini E,
et al: Inhibition of Notch pathway arrests PTEN-deficient advanced
prostate cancer by triggering p27-driven cellular senescence. Nat
Commun. 7:137192016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Piao HY, Guo S, Wang Y and Zhang J: Long
noncoding RNA NALT1-induced gastric cancer invasion and metastasis
via NOTCH signaling pathway. World J Gastroenterol. 25:6508–6526.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jena N, Sheng J, Hu JK, Li W, Zhou W, Lee
G, Tsichlis N, Pathak A, Brown N, Deshpande A, et al: CDK6-mediated
repression of CD25 is required for induction and maintenance of
Notch1-induced T-cell acute lymphoblastic leukemia. Leukemia.
30:1033–1043. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dong X, Hu X, Chen J, Hu D and Chen LF:
BRD4 regulates cellular senescence in gastric cancer cells via
E2F/miR-106b/p21 axis. Cell Death Dis. 9:2032018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Q, Xu S, Li X, Wang B, Wang X, Ma D,
Yang L, Peng J and Hou M: Pathway of Toll-like receptor 7/B cell
activating factor/B cell activating factor receptor plays a role in
immune thrombocytopenia in vivo. PLoS One. 6:e227082011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karimi P, Islami F, Anandasabapathy S,
Freedman ND and Kamangar F: Gastric cancer: Descriptive
epidemiology, risk factors, screening, and prevention. Cancer
Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dassen AE, Dikken JL, van de Velde CJ,
Wouters MW, Bosscha K and Lemmens VE: Changes in treatment patterns
and their influence on long-term survival in patients with stages
I–III gastric cancer in The Netherlands. Int J Cancer.
133:1859–1866. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Finn RS, Martin M, Rugo HS, Jones S, Im
SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, et al:
Palbociclib and letrozole in advanced breast cancer. N Engl J Med.
375:1925–1936. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lim S and Kaldis P: Cdks, cyclins and
CKIs: Roles beyond cell cycle regulation. Development.
140:3079–3093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xie X, Zheng W, Chen T, Lin W, Liao Z, Liu
J and Ding Y: CDK4/6 inhibitor palbociclib amplifies the
radiosensitivity to nasopharyngeal carcinoma cells via mediating
apoptosis and suppressing DNA damage repair. Onco Targets Ther.
12:11107–11117. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang G, Ma F, Li L, Li J, Li P, Zeng S,
Sun H and Li E: Palbociclib triggers apoptosis in bladder cancer
cells by Cdk2-induced Rad9-mediated reorganization of the
Bak.Bcl-xl complex. Biochem Oharmacol. 163:133–141. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Min A, Kim JE, Kim YJ, Lim JM, Kim S, Kim
JW, Lee KH, Kim TY, Oh DY, Bang YJ and Im SA: Cyclin E
overexpression confers resistance to the CDK4/6 specific inhibitor
palbociclib in gastric cancer cells. Cancer Lett. 430:123–132.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hornsby PJ: Senescence as an anticancer
mechanism. J Clin Oncol. 25:1852–1857. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cagnol S and Chambard JC: ERK and cell
death: Mechanisms of ERK-induced cell death-apoptosis, autophagy
and senescence. FEBS J. 277:2–21. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kovatcheva M, Liu DD, Dickson MA, Klein
ME, O'Connor R, Wilder FO, Socci ND, Tap WD, Schwartz GK, Singer S,
et al: MDM2 turnover and expression of ATRX determine the choice
between quiescence and senescence in response to CDK4 inhibition.
Oncotarget. 6:8226–8243. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Puyol M, Martin A, Dubus P, Mulero F,
Pizcueta P, Khan G, Guerra C, Santamaría D and Barbacid M: A
synthetic lethal interaction between K-Ras oncogenes and Cdk4
unveils a therapeutic strategy for non-small cell lung carcinoma.
Cancer Cell. 18:63–73. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ntziachristos P, Lim JS, Sage J and
Aifantis I: From Fly wings to targeted cancer therapies: A
centennial for notch signaling. Cancer Cell. 25:318–334. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Espinoza I and Miele L: Notch inhibitors
for cancer treatment. Pharmacol Ther. 139:95–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S,
Wu GS and Wu K: Notch signaling: An emerging therapeutic target for
cancer treatment. Cancer Lett. 369:20–27. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li N, Fassl A, Chick J, Inuzuka H, Li X,
Mansour MR, Liu L, Wang H, King B, Shaik S, et al: Cyclin C is a
haploinsufficient tumour suppressor. Nat Cell Biol. 16:1080–1091.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Joshi I, Minter LM, Telfer J, Demarest RM,
Capobianco AJ, Aster JC, Sicinski P, Fauq A, Golde TE and Osborne
BA: Notch signaling mediates G1/S cell-cycle progression in T cells
via cyclin D3 and its dependent kinases. Blood. 113:1689–1698.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xiu MX, Liu YM and Kuang BH: The oncogenic
role of Jagged1/Notch signaling in cancer. Biomed Pharmacother.
129:1104162020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hibdon ES, Razumilava N, Keeley TM, Wong
G, Solanki S, Shah YM and Samuelson LC: Notch and mTOR signaling
pathways promote human gastric cancer cell proliferation.
Neoplasia. 21:702–712. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Demitrack ES, Gifford GB, Keeley TM,
Horita N, Todisco A, Turgeon DK, Siebel CW and Samuelson LC: NOTCH1
and NOTCH2 regulate epithelial cell proliferation in mouse and
human gastric corpus. Am J Physiol Gastrointest Liver Physiol.
312:G133–G144. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gifford GB, Demitrack ES, Keeley TM, Tam
A, La Cunza N, Dedhia PH, Spence JR, Simeone DM, Saotome I, Louvi
A, et al: Notch1 and Notch2 receptors regulate mouse and human
gastric antral epithelial cell homoeostasis. Gut. 66:1001–1011.
2017. View Article : Google Scholar : PubMed/NCBI
|
